This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Cyramza
  • /
  • A Study of Ramucirumab (LY3009806) in Combination ...
Clinical trial

A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer (RAINFALL)

Read time: 2 mins
Last updated:1st Jan 2015
Identifier: NCT02314117

The main purpose of this study is to evaluate the effectiveness of ramucirumab, which is a targeted antibody, in combination with capecitabine and cisplatin compared to capecitabine and cisplatin alone in participants with stomach cancer.


Study Type: Interventional
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
Estimated Enrollment: 616
Study Start Date: January 2015
Estimated Study Completion Date: August 2018
Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)

Arms:
- Experimental:
Ramucirumab + Cisplatin + Capecitabine
- Active Comparator: Placebo + Cisplatin + Capecitabine

Category Value
Date last updated at source 2017-03-09
Study type(s) Interventional
Expected enrolment 616
Study start date 2015-01-01
Estimated primary completion date 2017-01-01

View full details